阿托伐他汀改善环磷酰胺诱导的早发性卵巢功能不全大鼠的卵巢功能与卵泡储备
该实验研究将24只成年雌性Wistar大鼠分为对照组、早发性卵巢功能不全(POI)组、POI+阿托伐他汀组和阿托伐他汀组。结果显示,与POI组相比,POI+阿托伐他汀组血清总抗氧化能力、谷胱甘肽、雌二醇和抗苗勒管激素升高,丙二醛、FSH、肿瘤坏死因子-α和白细胞介素-6降低,Bcl-2和VEGF-A表达升高、Bax表达降低,各级卵泡数及卵巢总体积和皮质体积增加。结论认为阿托伐他汀可减轻环磷酰胺对POI模型的有害影响。
要点
- POI+阿托伐他汀组较POI组血清总抗氧化能力(P < 0.001)、谷胱甘肽、雌二醇和抗苗勒管激素(P < 0.05)升高。
- POI+阿托伐他汀组较POI组丙二醛、FSH、肿瘤坏死因子-α和白细胞介素-6降低(P < 0.05)。
- POI+阿托伐他汀组较POI组原始和初级卵泡数(P < 0.001)、腔前和窦卵泡数(P < 0.01)增加。
核心结论
- 阿托伐他汀通过降低氧化应激和促炎细胞因子、调节Bax、Bcl-2和VEGF-A表达,显著减轻环磷酰胺对POI模型的有害影响,改善卵巢功能和卵泡储备。
研究设计与样本
- 实验研究,24只成年雌性Wistar大鼠分为四组:对照组、POI组、POI+阿托伐他汀组和阿托伐他汀组。
主要发现
- 与POI组相比,POI+阿托伐他汀组血清总抗氧化能力(P < 0.001)、谷胱甘肽、雌二醇和抗苗勒管激素(P < 0.05)升高。
- 与POI组相比,POI+阿托伐他汀组血清丙二醛、FSH、肿瘤坏死因子-α和白细胞介素-6降低(P < 0.05)。
- 与POI组相比,POI+阿托伐他汀组Bcl-2和VEGF-A的mRNA和蛋白表达升高(P < 0.05),Bax的mRNA和蛋白表达降低(P < 0.05)。
- 与POI组相比,POI+阿托伐他汀组原始和初级卵泡数(P < 0.001)、腔前和窦卵泡数(P < 0.01)增加。
- 与POI组相比,POI+阿托伐他汀组卵巢总体积和皮质体积增加(P < 0.05)。
关键数值与推荐
- 血清总抗氧化能力组间比较P < 0.001(POI+阿托伐他汀组 vs POI组,升高)。
- 血清谷胱甘肽、雌二醇、抗苗勒管激素组间比较P < 0.05(POI+阿托伐他汀组 vs POI组,升高)。
- 血清丙二醛、FSH、肿瘤坏死因子-α、白细胞介素-6组间比较P < 0.05(POI+阿托伐他汀组 vs POI组,降低)。
- Bcl-2和VEGF-A的mRNA和蛋白表达组间比较P < 0.05(POI+阿托伐他汀组 vs POI组,升高);Bax的mRNA和蛋白表达组间比较P < 0.05(POI+阿托伐他汀组 vs POI组,降低)。
- 原始和初级卵泡数组间比较P < 0.001(POI+阿托伐他汀组 vs POI组,增加);腔前和窦卵泡数组间比较P < 0.01(POI+阿托伐他汀组 vs POI组,增加);卵巢总体积和皮质体积组间比较P < 0.05(POI+阿托伐他汀组 vs POI组,增加)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Can atorvastatin, with its antioxidant, anti-inflammatory and anti-apoptotic properties, improve ovarian function and follicular reserve in rats with cyclophosphamide-induced premature ovarian insufficiency (POI)? DESIGN: In this experimental study, 24 adult female Wistar rats were divided into four groups: control; POI; POI + atorvastatin; and atorvastatin. After treatment with atorvastatin, serum concentrations of total antioxidant capacity, glutathione, malondialdehyde, FSH, oestradiol, anti-Müllerian hormone, tumour necrosis factor-alpha and interleukin-6 were evaluated. Additionally, mRNA and protein expression of Bax, Bcl-2 and VEGF-A; number of follicles; and total volume of the ovary, and volumes of the cortex and medulla were examined. RESULTS: The results showed that serum concentrations of total antioxidant capacity (P < 0.001), glutathione, oestradiol and anti-Müllerian hormone (P < 0.05); mRNA and protein expression of Bcl-2 and VEGF-A (P < 0.05); number of primordial and primary follicles (P < 0.001), and preantral and antral follicles (P < 0.01); and total volume of the ovary, and volume of the cortex (P < 0.05) increased significantly in the POI + atorvastatin group compared with the POI group. Serum concentrations of malondialdehyde, FSH, tumour necrosis factor-alpha and interleukin-6; and mRNA and protein expression of Bax decreased significantly in the POI + atorvastatin group compared with the POI group (P < 0.05). CONCLUSIONS: Atorvastatin reduces the detrimental effects of cyclophosphamide in the POI model significantly by reducing oxidative stress and pro-inflammatory cytokines; regulating the expression of Bax, Bcl-2 and VEGF-A; and improving ovarian function and follicular reserve.
引用
- Notghi P, Mehranjani MS, Shariatzadeh SMA, et al. Atorvastatin improves ovarian function and follicular reserve in rats with premature ovarian insufficiency. Reprod Biomed Online. 2024. PMID: 39197401. doi:10.1016/j.rbmo.2024.104324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。